Teclistamab Shows Promise for Patients with Relapsed/Refractory Myeloma

Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news